Expertise in
25
conditions

Dr. John C. Henegan

Oncology
MS State Board Of Health Paren
350 W Woodrow Wilson Ave, 
Jackson, MS 
Clinical Trials:Currently Recruiting for 1 Trial
Accepting New Patients
Offers Telehealth
Expertise in
25
conditions
MS State Board Of Health Paren
350 W Woodrow Wilson Ave, 
Jackson, MS 

Overview

John Henegan is an Oncologist practicing medicine in Jackson, Mississippi.

Dr. Henegan is highly rated in 25 conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Urothelial Cancer, Clear Cell Sarcoma, and Bone Marrow Aspiration.

He is actively involved in clinical research, co-authoring 11 peer reviewed articles and participating in 21 clinical trials. Dr. Henegan is currently accepting new patients.

Specialties

Oncology

Licenses

Internal Medicine in MS

Hospital Affiliations

Mississippi Baptist Medical Center
University Of Mississippi Med Center
Merit Health Madison
University Of Mississippi Medical Center- Grenada

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Devoted Health
  • MEDICARE MAPD
  • OTHER MEDICARE
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Magnolia Health
  • HMO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Primewell Health Services
  • HMO
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE PART D
  • POS
Quartz Health Plan
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Walgreens
  • MEDICARE DISCOUNT CARD
  • MEDICARE PDP
  • OTHER MEDICARE
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 9 Less Insurance Carriers -

Locations

MS State Board of Health Paren
350 W Woodrow Wilson Ave, Jackson, MS 39213
Other Locations
University Pathology Associates PLLC
2500 N State St, Jackson, MS 39216

Additional Areas of Focus

Dr. Henegan has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Metastatic Uveal Melanoma

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

21 Clinical Trials

Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Phase III Study of Local or Systemic Therapy INtensification DIrected by PET in Prostate CAncer Patients With Post-ProstaTEctomy Biochemical Recurrence (INDICATE)
Enrollment Status: Recruiting
Publish Date: August 19, 2026
Intervention Type: Procedure, Drug, Radiation, Other
Study Drugs: Apalutamide, Goserelin acetate, Leuprolide acetate
Study Phase: Phase 3
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drugs: Sacituzumab govitecan, Sacituzumab govitecan+Pembrolizumab, IMMU-132+Cisplatin, IMMU-132+Cisplatin+Avelumab
Study Phase: Phase 2
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab Vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated REnal Cell CancEr [PDIGREE]
Enrollment Status: Active_not_recruiting
Publish Date: August 31, 2026
Intervention Type: Other, Procedure, Drug, Biological
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 3
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Phase 2 Single Arm Trial of Cisplatin, Nab-Paclitaxel, and Cetuximab (CACTUX) in Patients With Incurable Head and Neck Squamous Cell Carcinoma (HNSCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological
Study Drugs: Nab-Paclitaxel, Cisplatin, Carboplatin, Cetuximab
Study Phase: Phase 2
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Phase III Randomized Adjuvant Study of Pembrolizumab in muScle invaSive and locAlly aDvanced urOthelial caRcinoma (AMBASSADOR) Versus Observation
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Pembrolizumab
Study Phase: Phase 3
Molecular Analysis for Therapy Choice (MATCH)
Molecular Analysis for Therapy Choice (MATCH)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Procedure, Drug, Other, Biological
Study Drugs: Adavosertib, Afatinib, Binimetinib, Capivasertib, Copanlisib, Crizotinib, Dabrafenib, Dasatinib, Defactinib, Erdafitinib, FGFR Inhibitor AZD4547, Ipatasertib, Larotrectinib, Nivolumab, Osimertinib, Palbociclib, Pertuzumab, PI3K-Beta Inhibitor GSK2636771, Sapanisertib, Sunitinib, Taselisib, Trametinib, Trastuzumab, Ulixertinib, Vismodegib
Study Phase: Phase 2
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
A Phase 3 RandOmized Study Comparing PERioperative Nivolumab vs. Observation in Patients With Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Biological, Procedure
Study Drug: Nivolumab
Study Phase: Phase 3
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
A Phase II, Double-Blinded, Placebo-Controlled Randomized Trial of Salvage Radiotherapy With or Without Enhanced Anti-Androgen Therapy With Apalutamide in Recurrent Prostate Cancer (BALANCE*)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Other, Radiation, Drug
Study Drug: Apalutamide
Study Phase: Phase 2
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Cabazitaxel With Abiraterone Versus Abiraterone Alone Randomized Trial for Extensive Disease Following Docetaxel: The CHAARTED2 Trial
Enrollment Status: Active_not_recruiting
Publish Date: August 06, 2026
Intervention Type: Drug
Study Drugs: Abiraterone acetate, Antiandrogen therapy, Cabazitaxel, Prednisone
Study Phase: Phase 2
A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
A Phase III Randomized Trial of Eribulin (NSC #707389) With Gemcitabine Versus Standard of Care (Physician's Choice) for Treatment of Metastatic Urothelial Carcinoma Refractory to, or Ineligible for, Anti PD1/PDL1 Therapy
Enrollment Status: Active_not_recruiting
Publish Date: August 04, 2026
Intervention Type: Procedure, Drug, Biological
Study Drugs: Docetaxel, Eribulin Mesylate, Gemcitabine Hydrochloride, Paclitaxel
Study Phase: Phase 3
View 9 Less Clinical Trials

11 Total Publications

BRCA2 and NF2-Mutated High-Grade Renal Cell Carcinoma: A Case Report and Literature Review.
BRCA2 and NF2-Mutated High-Grade Renal Cell Carcinoma: A Case Report and Literature Review.
Journal: International journal of surgical pathology
Published: February 24, 2026
Similar Doctors
Expertise in
10
conditions
Expertise in
10
conditions
Referral may be required

University Pathology Associates PLLC

2500 N State St, 
Jackson, MS 
 (1.4 miles away)
601-815-2005
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Rodney Rocconi is an Oncologist practicing medicine in Jackson, Mississippi. Dr. Rocconi is highly rated in 10 conditions, according to our data. His clinical expertise encompasses Ovarian Cancer, Endometrial Cancer, Ovarian Carcinosarcoma, and Cervical Cancer. Dr. Rocconi is currently accepting new patients.

Expertise in
78
conditions
Expertise in
78
conditions
Referral may be required

Merit Health Woman's Hospital

1026 N Flowood Dr, 
Flowood, MS 
 (5.5 miles away)
601-974-5600
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Tammy Young is an Oncologist practicing medicine in Flowood, Mississippi. Dr. Young is highly rated in 78 conditions, according to our data. Her clinical expertise encompasses Breast Cancer, Paget Disease of the Breast, Pleuropulmonary Blastoma, Lung Cancer, and Advanced Bronchoscopy. Dr. Young is currently accepting new patients.

Expertise in
17
conditions
Expertise in
17
conditions
Referral may be required

Merit Health Woman's Hospital

1026 N Flowood Dr, 
Flowood, MS 
 (5.5 miles away)
601-968-3238
Languages Spoken:
English
See accepted insurances
Accepting New Patients

James Moore is an Oncologist practicing medicine in Flowood, Mississippi. Dr. Moore is highly rated in 17 conditions, according to our data. His clinical expertise encompasses Vulvar Cancer, Endometrial Cancer, Malignant Mixed Mullerian Tumor, Bladder Reconstruction, and Ureteral Reconstruction. Dr. Moore is currently accepting new patients.

Frequently Asked Questions about Dr. John C. Henegan

How do I make an appointment with Dr. John C. Henegan?

You can book an appointment with Dr. John C. Henegan by calling their office at 601-815-6700. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. John C. Henegan a top-rated expert for Renal Cell Carcinoma (RCC)?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. John C. Henegan is classified as an Distinguished expert for Renal Cell Carcinoma (RCC), meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. John C. Henegan specialize in?

While Dr. John C. Henegan is a Oncology, they have specific expertise in Renal Cell Carcinoma (RCC), Familial Prostate Cancer, and Urothelial Cancer. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Oncology.

Does Dr. John C. Henegan participate in research or clinical trials?

Yes. Dr. John C. Henegan has published 11 articles and abstracts on conditions like Renal Cell Carcinoma (RCC). You can view a list of Dr. John C. Henegan's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. John C. Henegan accept my insurance?

Dr. John C. Henegan accepts most major insurance plans, including Aetna and Blue Cross Blue Shield. We recommend calling the office directly at 601-815-6700 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Henegan's expertise for a condition
ConditionClose
    View All 9 Distinguished Conditions
    View All 16 Advanced Conditions
    View All 50 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile